Phase
Condition
N/ATreatment
Mirabegron with vaginal estrogen cream
Solifenacin with vaginal estrogen cream
Combined pharmacotherapy with Solifenacin and Mirabegron
Clinical Study ID
Ages 40-90 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with detrusor overactivity which defined as a urodynamic observationcharacterized by involuntary detrusor contractions during the filling phase. Thosewho were refractory to monotherapy with anti-muscarinics were enrolled forprospective study.
Exclusion
Exclusion Criteria:
Postvoid urine retention before treatment
Women who had medical illness and contraindication for using solifenacin andmirabegron, such as narrow-angle glaucoma and hypertension
Concerns for using estrogen include: Women with history of cerebrovascular disease;thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma;estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.
Study Design
Study Description
Connect with a study center
Mackay Memorial Hospital
Taipei,
TaiwanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.